Wenyang Lishui Decoction Ameliorates Podocyte Injury in Membranous Nephropathy Rat and Cell Models by Regulating p53 and Bcl-2

الملخص EN

Wenyang Lishui decoction (WYD) has been frequently used to treat patients with membranous nephropathy (MN) in China.

Our previous study in vitro showed that WYD aqueous extract could alleviate F-actin reorganization of podocytes induced by serum from idiopathic membranous nephropathy (IMN) patients.

This study aims to investigate the effects and molecular mechanisms of WYD on MN.

MN rat models were induced by cationic bovine serum albumin.

Experimental rats were divided into four groups: normal, model, WYD, and benazepril.

The normal group consisted of normal rats receiving distilled water for four weeks, while the model, WYD, and benazepril groups consisted of MN rats receiving distilled water, 16.5 g/kg/day WYD aqueous extract, and 10 mg/kg/day benazepril, respectively.

Alanine aminotransferase, kidney function, albumin, and 24 h urine total protein (UTP) were measured.

Hematoxylin-eosin and electron microscopy analyses were performed.

Mouse podocytes were induced to develop cell models by serum from IMN patients with antibody to the M-type phospholipase A2 receptor and spleen and kidney Yang deficiency syndrome.

They were divided into five groups: control, model, 2 mg/ml WYD, 4 mg/ml WYD, and 8 mg/ml WYD.

CCK-8 assays, flow cytometry, qRT-PCR, and Western blot analyses were performed.

In the animal experiment, side effects of WYD were not found.

Also, there was no significant difference in kidney function among the groups.

In addition, UTP level was significantly reduced, and kidney histological damage was restored in both WYD and benazepril groups but difference in UTP level between them was not found.

In the cell experiment, apoptosis rate was increased in the model group while it was decreased by coincubation with WYD.

Besides, mRNA and protein levels of p53 were decreased, and those of Bcl-2 were increased by treatment using WYD.

In conclusion, WYD could reduce proteinuria and ameliorate podocyte injury by regulating the expression of p53 and Bcl-2.

The study is registered in the Chinese Clinical Trial Registry (ChiCTR-OCH-14005137).